Chemed Corporation’s fourth-quarter 2017 adjusted earnings per share (EPS) were $2.32, as compared with the year-ago figure of $2.10. The figure also surpassed the Zacks Consensus Estimate of $2.28.
Full-year 2017 adjusted EPS came in at $8.43, beating the Zacks Consensus Estimate of $8.38. Moreover, the figure improved from the year-ago number of $7.24.
Quarter in Details
Revenues in the quarter increased 6.2% year over year to $428.4 million, beating the Zacks Consensus Estimate of $422 million.
Net revenues in 2017 totaled $1.67 billion, outpacing the Zacks Consensus Estimate of $1.66 billion. The figure also improved from the year-ago number of $1.58 billion.
Chemed currently operates through two wholly-owned subsidiaries, namely, VITAS Healthcare Corporation (a major provider of end-of-life care) and Roto-Rooter (a leading commercial and residential plumbing and drain cleaning service provider).
In the fourth quarter, net revenues at VITAS Healthcare totaled $292.3 million, reflecting an increase of 2.8% year over year. Revenues were driven by a 0.8% increase in the average net Medicare reimbursement rate and a 4.7% rise in average daily census. However, this was partially offset by acuity mix shift which impacted revenues by 1.7% and 0.9% adverse impact on revenues due to Medicare Cap.
Chemed Corp. Price, Consensus and EPS Surprise
Roto-Rooter reported sales of $136.1 million in the fourth quarter, up 14.1% year over year. According to the company, revenues from water restoration increased 61.7% year over year to $22.1 million.
Gross margin expanded 110 basis points (bps) year over year to 31.9%. Adjusted operating margin contracted a nominal 10 bps to 15.2% in the quarter on a 14.6% rise in selling, general and administrative expenses to $71.6 million.
Chemed exited 2017 with total cash and cash equivalents of $11.1 million, down from $15.3 million at the end of 2016. The company had total debt of $91.2 million at the end of 2017, compared with $100 million a year ago. As of Dec 31, 2017, the company had approximately $288 million in undrawn borrowing capacity under its existing five-year credit agreement.
During the fourth quarter, the company did not repurchase shares. As of Dec 31, 2017, the company had $55.5 million of remaining shares under its repurchase authorization.
The company projects VITAS Healthcare revenue growth for 2018 in the range of 2.5% to 3.5%, prior to the Medicare Cap. Also, the admissions and Average Daily Census in 2018 are expected to increase 3% to 4%. Medicare Cap billing limitations are expected at around $5 million in 2018.
The Roto-Rooter business is likely to grow 4% to 5% in the full year. The guidance was backed by a 2% increase in job pricing and water restoration services growth.
Full-year adjusted EPS is expected to grow in the band of $10.60 to $10.85 as compared with $8.43 reported in 2017.
Chemed exited the fourth quarter on a solid note. Also, the company witnessed year-over-year growth in both the fronts. Moreover, we are encouraged to note that the company’s subsidiaries saw year-over-year revenue growth in the quarter. The expansion in gross margin and strong bottom-line projections also buoy optimism.
Further, reimbursement-related issues, seasonality in business, a competitive landscape and dependence on government mandates continue to pose challenges.
A few top-ranked stocks that reported solid results this earnings season are PetMed Express (PETS - Free Report) , PerkinElmer (PKI - Free Report) and Becton, Dickinson and Company (BDX - Free Report) . While PetMed sports a Zacks Rank #1 (Strong Buy), PerkinElmer and Becton, Dickinson carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported third-quarter fiscal 2018 adjusted earnings per share of 44 cents, up 88.3% from the prior-year quarter. Revenues rose 13.7% to $60.1 million.
PerkinElmer posted fourth-quarter 2017 adjusted earnings per share of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter.
Becton, Dickinson reported first-quarter fiscal 2018 adjusted earnings per share of $2.48, up 3.9% at constant currency. Revenues totaled $3.08 billion, up 3.7% at constant currency.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>